04 Nov How Much Weight Can You Lose on Tirzepatide? A Realistic Timeline
Medically reviewed by Elyssa Blissenbach, MD · Board Certified, American Boards of Internal Medicine & Obesity Medicine
Licensed to practice in FL, GA, SC, AL, VA, NC · NPI #1881601714 · Last reviewed: 2026-11-04
Key Takeaways
- Trial average: about 21% of body weight lost at 72 weeks on tirzepatide 15 mg (SURMOUNT-1) — roughly 47 lbs for a 225-lb person.
- The curve is gradual: roughly 2–3% by month 1, ~7% by month 3, ~13% by month 6, with loss continuing well into the second year.
- About 9 in 10 trial participants lost at least 5%; on higher doses, more than half lost 20% or more, and about a third lost 25%+.
- In a head-to-head trial, tirzepatide outperformed semaglutide (about 20% vs. 14% at 72 weeks) — but the best medication is the one your body tolerates and your physician can dose well.
On average, patients taking tirzepatide at the highest studied dose lose about 21% of their body weight over 72 weeks — the headline result of the SURMOUNT-1 clinical trial, versus about 3% for placebo. For someone starting at 225 pounds, that’s roughly 47 pounds. Lower doses still posted strong averages (about 15–19%), and like all GLP-1 medications, the loss isn’t linear: the first month is slow by design, the middle months are the steepest, and results keep accruing past the one-year mark.
Here’s the month-by-month shape, how tirzepatide compares with semaglutide, and what determines whether you land above or below the average.
What Does the Tirzepatide Weight Loss Timeline Look Like?
Approximate trial-average progression at full titration (individual results vary):
| Timeframe | Average Loss (% body weight) | At 225 lbs, roughly | What’s Happening |
|---|---|---|---|
| Month 1 | ~2–3% | ~5–6 lbs | Starting dose (2.5 mg) is a tolerability dose; appetite changes arrive before scale changes |
| Month 3 | ~7% | ~15 lbs | Dose stepping up every 4 weeks; the curve steepens |
| Month 6 | ~13% | ~29 lbs | At or near maintenance dose; steepest sustained loss |
| Month 12–18 | ~20–21% | ~45–47 lbs | Loss continues, gradually flattening toward a new set point |
Figures are drawn from the SURMOUNT-1 trial’s average trajectory at the 15 mg dose. Roughly 91% of participants on that dose lost at least 5% of body weight; more than half lost 20% or more, and about 36% lost at least a quarter of their starting weight.
Why Does Tirzepatide Tend to Beat Semaglutide’s Numbers?
Tirzepatide works on two gut-hormone receptors (GIP and GLP-1) rather than one, which appears to amplify both appetite reduction and metabolic effect. In SURMOUNT-5 — the first large head-to-head trial — tirzepatide averaged about 20% body-weight loss at 72 weeks versus about 14% for semaglutide. That said, averages aren’t destinies: plenty of patients thrive on semaglutide, which has its own deep track record, and tolerability or availability can make it the smarter pick. Our semaglutide vs. tirzepatide comparison and the four-brand breakdown cover how to choose.
Why Is the First Month So Slow?
Because it’s supposed to be. Tirzepatide starts at 2.5 mg — explicitly a tolerability dose, not a treatment dose — and steps up every four weeks as your GI system adapts. Judging the medication at week four is judging the warm-up. The honest checkpoint is month three, at a meaningfully higher dose. (Starting soon? Here’s our patient checklist for your first tirzepatide injection.)
What Determines Whether You Beat the Average?
- Protein intake. Rapid loss without adequate protein costs you muscle, which lowers metabolic rate and sets up regain. Protein-first eating is the single highest-leverage habit.
- Resistance training. Two or three sessions a week tells your body to keep muscle and burn fat.
- Dose management. Tirzepatide has six dose levels — more room to personalize than most GLP-1s, but only if follow-ups happen. Missed visits are a common, silent reason for below-average results.
- Consistency. Weekly injections on schedule; skipped weeks reset tolerance and momentum.
What Happens If You Stop?
The withdrawal data is blunt: in SURMOUNT-4, participants who stopped tirzepatide after their initial loss regained most of it within a year, while those who continued kept losing. The medication manages a chronic condition; stopping abruptly un-manages it. A supervised maintenance phase — adjusted dosing with locked-in protein and training habits — is how results survive.
How Do You Start?
Tirzepatide (Mounjaro, Zepbound) is a prescription medication, and the screening matters: thyroid history, pancreatitis history, other medications, and your labs all factor in. Our tirzepatide program in Jacksonville pairs the medication with physician supervision from Dr. Blissenbach — in person or by telehealth. Curious what your realistic number looks like? Schedule a free consultation.
Frequently Asked Questions
How much weight will I lose in the first month on tirzepatide?
Typically a few pounds — often around 2–3% of body weight. The first month is titration: you’re on the lowest dose while your body adapts. Meaningful appetite change usually shows before meaningful scale change.
Is tirzepatide better than semaglutide for weight loss?
On trial averages, yes — roughly 20% vs. 14% at 72 weeks in the head-to-head SURMOUNT-5 trial. But individual response, side-effect tolerance, and availability matter more than averages, which is why the choice is made with a physician.
What if I’m not losing weight on tirzepatide?
Less than 5% lost after about three months at a therapeutic dose is the usual threshold for a strategy conversation: adjusting the dose, tightening nutrition, or reassessing fit. With six dose levels, there’s usually room to optimize before switching.
Will I regain the weight if I stop tirzepatide?
Without a maintenance plan, most people regain much of it — that’s what the SURMOUNT-4 trial found. A supervised taper or maintenance protocol, plus preserved muscle from protein and training, is what protects your results.
Image: Getskinnyjax.com